Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Levison, Julie H ^a,c   Orrell, Catherine ^b   Gallien, Sébastien ^c,e   Kuritzkes, Daniel R ^c,e   Fu, Naishin ^a   Losina, Elena ^a,d,e   Freedberg, Kenneth A ^a,d,e   Wood, Robin ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^e HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; RETROSPECTIVE STUDY; SOUTH AFRICA; TREATMENT FAILURE; WILD TYPE; ANTIVIRAL RESISTANCE; DRUG EFFECT; FLOW CYTOMETRY; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; STATISTICS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; FLOW CYTOMETRY; HIV INFECTIONS; HIV-1; HUMANS; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, RNA; SOUTH AFRICA; TREATMENT FAILURE;

EID: 84858110511     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032144     Document Type: Article

References (40)

1. UNAIDS Joint United Nations Programme on HIV/AIDS (2010) Country Fact Sheets: South Africa. Available: http://cfs.unaids.org/factsheet.htm?lng_code=en. Accessed: 2011 June 14.
2. Long L, Fox M, Sanne I, Rosen S, (2010) The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. AIDS 24: 915-919.
3. World Health Organization (2007) Prioritizing Second-Line Antiretroviral Drugs for Adults and Adolescents: A Public Health Approach Geneva World Health Organization, HIV Department Available: http://www.who.int/hiv/pub/meetingreports/Second_Line_Antiretroviral.pdf. Accessed: 2012 February 8.
4. Orrell C, Walensky RP, Losina E, Pitt J, Freedberg KA, et al. (2009) HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther 14: 523-531.
5. Walmsley S, Bernstein B, King M, Arribas J, Beall G, et al. (2002) Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 346: 2039-2046.
6. Murphy RA, Sunpath H, Lu Z, Chelin N, Losina E, et al. (2010) Outcomes after virologic failure of first-line ART in South Africa. AIDS 24: 1007-1012.
7. Hosseinipour MC, Kumwenda JJ, Weigel R, Brown LB, Mzinganjira D, et al. (2010) Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med 11: 510-518.
8. Fox MP, Ive P, Long L, Maskew M, Sanne I, (2009) High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 53: 500-506.
9. Levison JH, Orrell C, Losina E, Lu Z, Freedberg KA, et al. (2011) Early outcomes and the virological effect of delayed treatment switching to second-line therapy in an antiretroviral roll-out programme in South Africa. Antivir Ther 16: 853-861.
10. Marconi VC, Sunpath H, Lu Z, Gordon M, Koranteng-Apeagyei K, et al. (2008) Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 46: 1589-1597.
11. Hemelaar J, Gouws E, Ghys PD, Osmanov S, (2011) Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 25: 679-689.
12. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R, (2005) Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 19: 2141-2148.
13. Orrell C, Harling G, Lawn SD, Kaplan R, McNally M, et al. (2007) Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther 12: 83-88.
14. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, et al. (2004) Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 18: 887-895.
15. National Department of Health South Africa Clinical Guidelines for the Management of HIV and AIDS in Adults and Adolescents, 2010. Available: http://www.fidssa.co.za/Guidelines/2010_Adult_ART_Guidelines.pdf. Accessed: 2012 February 8.
16. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, et al. (2010) Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 18: 156-163.
17. Wallis CL, Papathanasopoulos MA, Lakhi S, Karita E, Kamali A, et al. (2010) Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. J Virol Methods 163: 505-508.
18. Kunches LM, Reinhalter NE, Marquis A, Coakley E, Cohen C, et al. (2001) Tolerability of enteric-coated didanosine capsules compared with didanosine tablets in adults with HIV infection. J Acquir Immune Defic Syndr 28: 150-153.
19. Barreiro P, Corbaton A, Nunez M, Gonzalez-Lahoz J, Soriano V, (2004) Tolerance of didanosine as enteric-coated capsules versus buffered tablets. AIDS Patient Care STDS 18: 329-331.
20. Miller CM, Ketlhapile M, Rybasack-Smith H, Rosen S, (2010) Why are antiretroviral treatment patients lost to follow-up? A qualitative study from South Africa. Trop Med Int Health 15 (Suppl 1): 48-54.
21. Pasquet A, Messou E, Gabillard D, Minga A, Depoulosky A, et al. (2010) Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Cote d'Ivoire. PLoS One 5: e13414.
22. Geng EH, Bangsberg DR, Musinguzi N, Emenyonu N, Bwana MB, et al. (2010) Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr 53: 405-411.
23. Bellocchi MC, Forbici F, Palombi L, Gori C, Coelho E, et al. (2005) Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme. J Med Virol 76: 452-458.
24. Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, et al. (2000) Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 38: 3919-3925.
25. Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, et al. (2005) Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2: e112.
26. Grossman Z, Vardinon N, Chemtob D, Alkan ML, Bentwich Z, et al. (2001) Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B. AIDS 15: 1453-1460.
27. Frater AJ, Beardall A, Ariyoshi K, Churchill D, Galpin S, et al. (2001) Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients. AIDS 15: 1493-1502.
28. Velazquez-Campoy A, Todd MJ, Vega S, Freire E, (2001) Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proc Natl Acad Sci U S A 98: 6062-6067.
29. Wallis CL, Mellors JW, Venter WDF, Sanne I, Stevens W, (2011) Protease inhibitor resistance is uncommon in HIV-1 subtype C infected patients on failing second-line lopinavir/r-containing antiretroviral therapy in South Africa. AIDS Research and Treatment 2011: 769627.
30. El-Khatib Z, Ekstrom AM, Ledwaba J, Mohapi L, Laher F, et al. (2010) Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS 24: 1679-1687.
31. World Health Organization (2010) Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector. Available: http://www.who.int/hiv/pub/towards_universal_access_report_2008.pdf. Accessed: 2012 February 8.
32. Li JF, Lipscomb JT, Wei X, Martinson NA, Morris L, et al. (2011) Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naive chronic and acute HIV-1 subtype C infections. J Infect Dis 203: 798-802.
33. Ross LL, Rouse E, Gerondelis P, DeJesus E, Cohen C, et al. (2010) Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir. J Antimicrob Chemother 65: 307-315.
34. Bekker LG, Myer L, Orrell C, Lawn S, Wood R, (2006) Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Gugulethu, South Africa. S Afr Med J 96: 315-320.
35. Nash D, Katyal M, Brinkhof MW, Keiser O, May M, et al. (2008) Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS 22: 2291-2302.
36. Decloedt EH, McIlleron H, Smith P, Merry C, Orrell C, et al. (2011) Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets. Antimicrob Agents Chemother 55: 3195-3200.
37. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, et al. (2011) Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 305: 1327-1335.
38. Gupta R, Hill A, Sawyer AW, Pillay D, (2008) Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 47: 712-722.
39. Walmsley S, Loutfy M, (2002) Can structured treatment interruptions (STIs) be used as a strategy to decrease total drug requirements and toxicity in HIV infection? J Int Assoc Physicians AIDS Care (Chic Ill) 1: 95-103.
40. Mo H, King MS, King K, Molla A, Brun S, et al. (2005) Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates. J Virol 79: 3329-3338.